Management of patients with advanced gastrointestinal stromal tumor: Emphasis on fourth-line treatment with ripretinib

Treatment of gastrointestinal stromal tumors (GISTs), the most common gastrointestinal sarcoma, has been transformed by tyrosine kinase inhibitors, including ripretinib as a fourth-line therapy. This case study of a 65-year-old woman with advanced GIST who underwent treatment with imatinib, sunitinib, regorafenib, and ripretinib, emphasizes that effective management of heavily pretreated patients requires individualized care, addressing side effects, and educating patients. Advanced practitioners play a vital role in optimizing outcomes and supporting patient-centered care.